Value Investor
Start free

Agios Pharmaceuticals

AGIO on Nasdaq. Pharmaceutical preparations. Market value $1.9bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Not a fit for our list right now

Why it could be worth it

Nothing stands out yet.

What to watch out for

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
-19.3%low

For every $100 of what the whole company costs, it produced $-19.29 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: not known. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$31.72 a share, 43% above its 1-year low

Over the past year the price has ranged from $22.24 to $46.00.

Pays no dividend

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

-0.4
-0.3
-0.3
-0.4
-0.4
-0.4
2021202220232024202512 monthsto Jun '26
Revenue
$0$14m$27m$36m$54m
Operating margin
n/a-2732.1%-1459.5%-1166.5%-873.9%
Debt to equity
n/an/an/an/an/a
Shares outstanding
0.05bn0.06bn0.06bn0.06bn0.06bn

Health checks

  • Free cash flow positive0 of 5 years
  • Accounting checksSkipped: company is not yet profitable
  • DebtUnknown
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesNo, 9% more shares since 2021

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $45 million last quarter, up 259% on a year ago.
  • A loss of $101 million, compared with a loss of $112 million a year ago.
  • It loses 467 cents on each $1 of sales, compared with 1129 cents a year earlier.
  • Over the past 12 months it spent $365 million more cash than it brought in, compared with $409 million a year earlier.
  • 3% more shares than a year ago. Each share owns a bit less of the company.
  • Sales grew on a year ago in each of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$9m
December 2024$11m
March 2025$9m
June 2025$12m
September 2025$13m
December 2025$20m
March 2026$21m
June 2026$45m
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024$948m
December 2024-$97m
March 2025-$89m
June 2025-$112m
September 2025-$103m
December 2025-$108m
March 2026-$99m
June 2026-$101m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
12 February 2026
Next quarterly (estimated, 10-Q)
29 October 2026

Who owns it

None of the long-term investors we follow own it. 238 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

8 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 8 sold $5m, $5m of it under preset trading plans.

  • Gheuens Sarah
    Chief Medical Officer
    Sold
    under a preset trading plan
    Date
    4 August 2026
    Shares
    30,000
    Price
    $30.48
    Value
    $914,400
  • Gheuens Sarah
    Chief Medical Officer
    Sold
    under a preset trading plan
    Date
    1 July 2026
    Shares
    4,007
    Price
    $37.56
    Value
    $150,503
  • Burns James William
    Chief Legal Officer
    Sold
    under a preset trading plan
    Date
    2 April 2026
    Shares
    3,280
    Price
    $34.71
    Value
    $113,849
  • Gheuens Sarah
    Chief Medical Officer
    Sold
    under a preset trading plan
    Date
    2 April 2026
    Shares
    2,940
    Price
    $34.71
    Value
    $102,047
  • Jones Cecilia
    Chief Financial Officer
    Sold
    under a preset trading plan
    Date
    2 April 2026
    Shares
    3,141
    Price
    $34.71
    Value
    $109,024
  • Milanova Tsveta
    Chief Commercial Officer
    Sold
    under a preset trading plan
    Date
    2 April 2026
    Shares
    3,262
    Price
    $34.71
    Value
    $113,224
  • Viswanadhan Krishnan
    Chief Corp Dev & Strategy
    Sold
    under a preset trading plan
    Date
    2 April 2026
    Shares
    2,959
    Price
    $34.71
    Value
    $102,707
  • Goff Brian
    Chief Executive Officer, Director
    Sold
    under a preset trading plan
    Date
    2 April 2026
    Shares
    19,068
    Price
    $34.71
    Value
    $661,850
  • Viswanadhan Krishnan
    Chief Corp Dev & Strategy
    Sold
    under a preset trading plan
    Date
    5 March 2026
    Shares
    2,959
    Price
    $27.80
    Value
    $82,260
  • Washburn Theodore James Jr.
    Principal Accounting Officer
    Sold
    Date
    3 March 2026
    Shares
    5,272
    Price
    $28.88
    Value
    $152,255

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the serious warning signs we check for were found. 1 thing worth knowing.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 12 Feb 2026, plus the 10-Q filed 30 Jul 2026 and 3 later 8-Ks.

  • One big customer

    Worth knowing

    One customer brings in a big share of sales: 89% last year. Losing that customer would hurt.

    “One Customer accounted for 89 %, 95 % and 96 % of our consolidated revenues for the years ended December 31, 2025, 2024 and 2023, respectively, and 55 % and 92 % of accounts receivable from product sales for the years ended December 31, 2025 and 2024, respectively.”

    From the 10-K filed 12 February 2026, Item 8. Financial Statements and Notes. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.